[Thrombocytopenia in a patient with coronary artery disease after percutaneous coronary intervention].
Thrombocytopenia in patients with percutanous coronary intervention is a known complication of glycoprotein IIb/IIIa inhibitors. This can limit the application of these agents. Platelet count monitoring 2, 6, 12 and 24 hours after starting the treatment reveals most cases of acute thrombocytopenia. Side effects can be avoided by the early discontinuation of the glycoprotein IIb/IIIa antagonist treatment. A selective diagnostic approach by laboratory measures should exclude any confusion with heparin-induced thrombocytopenia and pseudo thrombocytopenia.